RxDoctor Payments Data

Britni Johnson, NP

Gerontology · Savannah, GANPI 1881375723

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (44.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 43.5% of the total. 2025 is the largest year on record at $15,859, more than ten times the $1,537 reported in 2023. Among gerontology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$23,887in general payments, 2019–2025

Across 349 payments — averaging $68.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$10K
  • Lilly USA, LLC$4K
  • Eisai Inc.$3K
  • AbbVie$717
  • TG Therapeutics, Inc.$677
  • UCB, Inc.$428
  • plus $5K from 41 others

What the payments were for

  • Consulting fees$2,47310%
  • Speaking & faculty fees$10,62944%
  • Travel & lodging$3,12213%
  • Food & beverage$7,63132%
  • Education$330%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,887 in reported general payments places this provider in the 95th percentile of 197 gerontology providers in Georgia.

See all gerontology providers in Georgia

Medicare billing

Part B allowed, 2024
$21,789
Medicare patients
79
Services billed
374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole32$53,875
Donepezil Hcl15$119
Memantine Hcl11$117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$10,399$53,87532 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 197 gerontology providers in Georgia.

Other gerontology in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →